Medarex/MedImmune begin dosing in Ph I MEDI-545 trial
Medarex says that its partner, fellow US drugmaker MedImmune, has begun dosing patients in a Phase I clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus. The agent is a fully-human antibody generated by Medarex' UltiMAb Human Antibody Development System. The randomized, 45-patient, double-blind, placebo-controlled, dose-escalation study involves a single intravenous shot of the anti-interferon-alpha antibody in patients who have mild SLE with lupus rash or skin lesions and is expected to enroll patients in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze